# Blackline, Inc.: financial statements, quarterly

BL · Nasdaq · CIK 1666134 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bl.md) · [Financials](/companies/bl/financials.md) · [Filings](/companies/bl/filings.md) · [Insiders](/companies/bl/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bl/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [151](/filings/0001666134-24-000019.md) | [156 d](/filings/0001628280-26-011915.md) | [157](/filings/0001666134-25-000016.md) | [161](/filings/0001666134-25-000031.md) | [166](/filings/0001628280-25-050628.md) | [169 d](/filings/0001628280-26-011915.md) | [167](/filings/0001628280-26-032255.md) | [172](/filings/0001628280-26-053353.md) | [178](/filings/0001628280-25-050628.md) | [183 d](/filings/0001628280-26-011915.md) | [183](/filings/0001628280-26-032255.md) | [188](/filings/0001628280-26-053353.md) |
| Cost of revenue | $m | [36.8](/filings/0001666134-24-000019.md) | [37.6 d](/filings/0001628280-26-011915.md) | [39.1](/filings/0001666134-25-000016.md) | [40.3](/filings/0001666134-25-000031.md) | [41.1](/filings/0001628280-25-050628.md) | [41.4 d](/filings/0001628280-26-011915.md) | [40.9](/filings/0001628280-26-032255.md) | [42.6](/filings/0001628280-26-053353.md) | [44.4](/filings/0001628280-25-050628.md) | [45.5 d](/filings/0001628280-26-011915.md) | [44.0](/filings/0001628280-26-032255.md) | [45.1](/filings/0001628280-26-053353.md) |
| Gross profit | $m | [114](/filings/0001666134-24-000019.md) | [118 d](/filings/0001628280-26-011915.md) | [118](/filings/0001666134-25-000016.md) | [120](/filings/0001666134-25-000031.md) | [125](/filings/0001628280-25-050628.md) | [128 d](/filings/0001628280-26-011915.md) | [126](/filings/0001628280-26-032255.md) | [129](/filings/0001628280-26-053353.md) | [134](/filings/0001628280-25-050628.md) | [138 d](/filings/0001628280-26-011915.md) | [139](/filings/0001628280-26-032255.md) | [143](/filings/0001628280-26-053353.md) |
| Research and development | $m | [26.7](/filings/0001666134-24-000019.md) | [22.6 d](/filings/0001628280-26-011915.md) | [25.0](/filings/0001666134-25-000016.md) | [25.7](/filings/0001666134-25-000031.md) | [25.6](/filings/0001628280-25-050628.md) | [24.6 d](/filings/0001628280-26-011915.md) | [25.7](/filings/0001628280-26-032255.md) | [28.0](/filings/0001628280-26-053353.md) | [27.3](/filings/0001628280-25-050628.md) | [28.2 d](/filings/0001628280-26-011915.md) | [30.6](/filings/0001628280-26-032255.md) | [31.3](/filings/0001628280-26-053353.md) |
| Operating income | $m | [(1.1)](/filings/0001666134-24-000019.md) | [12.8 d](/filings/0001628280-26-011915.md) | [1.7](/filings/0001666134-25-000016.md) | [2.2](/filings/0001666134-25-000031.md) | [8.4](/filings/0001628280-25-050628.md) | [6.2 d](/filings/0001628280-26-011915.md) | [3.6](/filings/0001628280-26-032255.md) | [7.5](/filings/0001628280-26-053353.md) | [7.6](/filings/0001628280-25-050628.md) | [6.8 d](/filings/0001628280-26-011915.md) | [6.2](/filings/0001628280-26-032255.md) | [11.0](/filings/0001628280-26-053353.md) |
| Interest expense | $m | [1.5](/filings/0001666134-23-000014.md) | [1.5 d](/filings/0001666134-24-000003.md) | [1.5](/filings/0001666134-24-000013.md) | [2.1](/filings/0001666134-25-000031.md) | [2.7](/filings/0001628280-25-050628.md) | [2.5 d](/filings/0001628280-26-011915.md) | [2.5](/filings/0001628280-26-032255.md) | [2.5](/filings/0001628280-26-053353.md) | [2.5](/filings/0001628280-25-050628.md) | [2.5 d](/filings/0001628280-26-011915.md) | [2.5](/filings/0001628280-26-032255.md) | [2.4](/filings/0001628280-26-053353.md) |
| Income tax | $m | [(2.0)](/filings/0001666134-24-000019.md) | [1.9 d](/filings/0001628280-26-011915.md) | [0.9](/filings/0001666134-25-000016.md) | [4.3](/filings/0001666134-25-000031.md) | [2.1](/filings/0001628280-25-050628.md) | [(50.4) d](/filings/0001628280-26-011915.md) | [4.7](/filings/0001628280-26-032255.md) | [6.2](/filings/0001628280-26-053353.md) | [4.7](/filings/0001628280-25-050628.md) | [5.5 d](/filings/0001628280-26-011915.md) | [5.9](/filings/0001628280-26-032255.md) | [3.5](/filings/0001628280-26-053353.md) |
| Net income | $m | [11.9](/filings/0001666134-24-000019.md) | [22.1 d](/filings/0001628280-26-011915.md) | [10.8](/filings/0001666134-25-000016.md) | [76.7](/filings/0001666134-25-000031.md) | [17.2](/filings/0001628280-25-050628.md) | [56.4 d](/filings/0001628280-26-011915.md) | [6.1](/filings/0001628280-26-032255.md) | [8.3](/filings/0001628280-26-053353.md) | [5.3](/filings/0001628280-25-050628.md) | [4.9 d](/filings/0001628280-26-011915.md) | [8.1](/filings/0001628280-26-032255.md) | [16.5](/filings/0001628280-26-053353.md) |
| Diluted EPS | $ per share | [0.19](/filings/0001666134-24-000019.md) | not reported | [0.17](/filings/0001666134-25-000016.md) | [0.22](/filings/0001666134-25-000031.md) | [0.27](/filings/0001628280-25-050628.md) | not reported | [0.10](/filings/0001628280-26-032255.md) | [0.13](/filings/0001628280-26-053353.md) | [0.09](/filings/0001628280-25-050628.md) | not reported | [0.13](/filings/0001628280-26-032255.md) | [0.27](/filings/0001628280-26-053353.md) |
| Basic EPS | $ per share | [0.20](/filings/0001666134-24-000019.md) | not reported | [0.18](/filings/0001666134-25-000016.md) | [1.24](/filings/0001666134-25-000031.md) | [0.28](/filings/0001628280-25-050628.md) | not reported | [0.10](/filings/0001628280-26-032255.md) | [0.13](/filings/0001628280-26-053353.md) | [0.09](/filings/0001628280-25-050628.md) | not reported | [0.14](/filings/0001628280-26-032255.md) | [0.28](/filings/0001628280-26-053353.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [236](/filings/0001666134-24-000019.md) | [271](/filings/0001628280-26-011915.md) | [331](/filings/0001666134-25-000016.md) | [617](/filings/0001666134-25-000031.md) | [725](/filings/0001628280-25-050628.md) | [886](/filings/0001628280-26-011915.md) | [480](/filings/0001628280-26-032255.md) | [459](/filings/0001628280-26-053353.md) | [420](/filings/0001628280-25-050628.md) | [390](/filings/0001628280-26-053353.md) | [242](/filings/0001628280-26-032255.md) | [243](/filings/0001628280-26-053353.md) |
| Current assets | $m | [1,319](/filings/0001666134-23-000014.md) | [1,407](/filings/0001666134-25-000003.md) | [1,404](/filings/0001666134-24-000013.md) | [1,210](/filings/0001666134-24-000016.md) | [1,013](/filings/0001666134-24-000019.md) | [1,092](/filings/0001628280-26-011915.md) | [1,043](/filings/0001666134-25-000016.md) | [1,056](/filings/0001666134-25-000031.md) | [984](/filings/0001628280-25-050628.md) | [1,025](/filings/0001628280-26-053353.md) | [732](/filings/0001628280-26-032255.md) | [748](/filings/0001628280-26-053353.md) |
| Total assets | $m | [2,016](/filings/0001666134-23-000014.md) | [2,101](/filings/0001666134-25-000003.md) | [2,089](/filings/0001666134-24-000013.md) | [1,891](/filings/0001666134-24-000016.md) | [1,695](/filings/0001666134-24-000019.md) | [1,825](/filings/0001628280-26-011915.md) | [1,781](/filings/0001666134-25-000016.md) | [1,793](/filings/0001666134-25-000031.md) | [1,704](/filings/0001628280-25-050628.md) | [1,760](/filings/0001628280-26-053353.md) | [1,456](/filings/0001628280-26-032255.md) | [1,469](/filings/0001628280-26-053353.md) |
| Current liabilities | $m | [606](/filings/0001666134-23-000014.md) | [643](/filings/0001666134-25-000003.md) | [610](/filings/0001666134-24-000013.md) | [620](/filings/0001666134-24-000016.md) | [377](/filings/0001666134-24-000019.md) | [422](/filings/0001628280-26-011915.md) | [630](/filings/0001666134-25-000016.md) | [644](/filings/0001666134-25-000031.md) | [647](/filings/0001628280-25-050628.md) | [695](/filings/0001628280-26-053353.md) | [430](/filings/0001628280-26-032255.md) | [435](/filings/0001628280-26-053353.md) |
| Total liabilities | $m | [1,773](/filings/0001666134-23-000014.md) | [1,810](/filings/0001666134-25-000003.md) | [1,775](/filings/0001666134-24-000013.md) | [1,533](/filings/0001666134-24-000016.md) | [1,298](/filings/0001666134-24-000019.md) | [1,342](/filings/0001628280-26-011915.md) | [1,327](/filings/0001666134-25-000016.md) | [1,344](/filings/0001666134-25-000031.md) | [1,337](/filings/0001628280-25-050628.md) | [1,388](/filings/0001628280-26-053353.md) | [1,118](/filings/0001628280-26-032255.md) | [1,128](/filings/0001628280-26-053353.md) |
| Shareholders' equity | $m | [216](/filings/0001666134-24-000019.md) | [261](/filings/0001628280-26-011915.md) | [280](/filings/0001666134-25-000031.md) | [326](/filings/0001628280-25-050628.md) | [368](/filings/0001628280-25-050628.md) | [447](/filings/0001628280-26-053353.md) | [418](/filings/0001628280-26-053353.md) | [414](/filings/0001628280-26-053353.md) | [328](/filings/0001628280-25-050628.md) | [332](/filings/0001628280-26-053353.md) | [306](/filings/0001628280-26-053353.md) | [316](/filings/0001628280-26-053353.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [37.0 d](/filings/0001666134-24-000019.md) | [42.2 d](/filings/0001628280-26-011915.md) | [50.4](/filings/0001666134-25-000016.md) | [40.7 d](/filings/0001666134-25-000031.md) | [55.9 d](/filings/0001628280-25-050628.md) | [43.8 d](/filings/0001628280-26-011915.md) | [46.7](/filings/0001628280-26-032255.md) | [32.3 d](/filings/0001628280-26-053353.md) | [63.8 d](/filings/0001628280-25-050628.md) | [26.7 d](/filings/0001628280-26-011915.md) | [46.3](/filings/0001628280-26-032255.md) | [45.0 d](/filings/0001628280-26-053353.md) |
| Capital expenditure | $m | [1.1 d](/filings/0001666134-24-000019.md) | [2.0 d](/filings/0001628280-26-011915.md) | [0.3](/filings/0001666134-25-000016.md) | [0.7 d](/filings/0001666134-25-000031.md) | [0.4 d](/filings/0001628280-25-050628.md) | [0.8 d](/filings/0001628280-26-011915.md) | [6.0](/filings/0001628280-26-032255.md) | [1.0 d](/filings/0001628280-26-053353.md) | [0.5 d](/filings/0001628280-25-050628.md) | [0.6 d](/filings/0001628280-26-011915.md) | [2.1](/filings/0001628280-26-032255.md) | [1.9 d](/filings/0001628280-26-053353.md) |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001666134-25-000016.md) | [0.0 d](/filings/0001666134-25-000031.md) | [0.0 d](/filings/0001628280-25-050628.md) | [0.0 d](/filings/0001628280-26-011915.md) | [45.5](/filings/0001628280-26-032255.md) | [43.3 d](/filings/0001628280-26-053353.md) | [112 d](/filings/0001628280-25-050628.md) | [34.8 d](/filings/0001628280-26-011915.md) | [46.0](/filings/0001628280-26-032255.md) | [38.5 d](/filings/0001628280-26-053353.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [59.7](/filings/0001666134-23-000014.md) | [60.2](/filings/0001666134-24-000013.md) | [71.8](/filings/0001666134-24-000016.md) | [72.1](/filings/0001666134-24-000019.md) | [72.9](/filings/0001666134-25-000016.md) | [72.5](/filings/0001666134-25-000031.md) | [74.0](/filings/0001628280-25-050628.md) | [64.8](/filings/0001628280-26-032255.md) | [64.0](/filings/0001628280-26-053353.md) | [63.2](/filings/0001628280-25-050628.md) | [69.8](/filings/0001628280-26-032255.md) | [68.6](/filings/0001628280-26-053353.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 58,125,270 at 2026-07-31, from the cover of the [10-Q filed 2026-08-05](/filings/0001628280-26-053353.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.